Effects of quercetin on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1411-1416

  Xiuguo, Li ^a   Choi, Jun Shik ^b  

^a YANBIAN UNIVERSITY   (China)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; CYP3A; Etoposide; P gp; Pharmacokinetics; Quercetin; Rats

Indexed keywords

CYTOCHROME P450 3A; ETOPOSIDE; GLYCOPROTEIN P; QUERCETIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INHIBITION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; DRUG INTERACTIONS; ETOPOSIDE; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 64949088858     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Clark PI and Slevin ML: The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12: 223-252, 1987.
2. Van Maanen JM, de Vries J, Pappie D, van den Akker E, Lafleur VM, Retel J, van der Greef J and Pinedo HM: Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res 47: 4658-4662, 1987.
3. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ and Korzekwa KR: O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45: 352-358, 1994.
4. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K and Ishizaki T: A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 286: 1294-1300, 1998.
5. Leu BL and Huang JD: Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35: 432-436, 1995.
6. Kan WM, Liu YT, Hsiao CL, Shieh CY, Kuo JH, Huang JD and Su SF: Effect of hydroxyzine on the transport of etoposide in rat small intestine. Anticancer Drugs 12: 267-273, 2001.
7. Kiviranta J, Huovinen K and Hiltunen R: Variation of phenolic substances in onion. Acta Pharm Fenn 97: 67-72, 1988.
8. Hertog MG, Hollman PC, Katan MB and Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. Nutr Cancer 20: 21-29, 1993.
9. Lamson DW and Brignall MS: Antioxidants and cancer III: quercetin. Alternative Medicine 5: 196-208, 2000.
10. Takahama U: Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: mechanism of antioxidative function. Phytochemistry 24: 1443-1446, 1985.
11. Ohnishi E and Bannai H: Quercetin potentiates TNF-induced antiviral activity. Antiviral Res 22: 327-331, 1993.
12. Alarcon de la Lastra C, Martin MJ and Motilva V: Antiulcer and gastroprotective effects of quercetin: a gross and histologic study. Pharmacology 48: 56-62, 1994.
13. Murray MT: Quercetin: nature's antihistamine. Better Nutrition 60: 10, 1998.
14. Knekt P, Jarvinen R, Seppanen R, Hellovaara M, Teppo L, Pukkala E and Aromaa A: Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 146: 223-230, 1997.
15. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A and Nedeljkovic S: Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch Intern Med 155: 381-386, 1995.
16. Rimm EB, Katan MB, Ascherio A, Stampfer MJ and Willett WC: Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 725: 384-389, 1996.
17. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C and Cianfriglia M: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464, 1994.
18. Guengerich FP and Kim HD: In vitro inhibition of dihydropyridine oxidation and aflatoxin Bl activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11: 2275-2279, 1990.
19. Miniscalco A, Lundahl J, Regardh CG, Edgar B and Eriksson UG: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J harmacol Exp Ther 261: 1195-1199, 1992.
20. Cooray HC, Janvilisri T, Van Veen HW, Hladky SB and Barrand MA: Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317: 269-275, 2004.
21. Van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, Bladeren PJ, Rietjens IM and Cnubben NH: Quantitative structure activity relationship studies on the flavonoid-mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 69: 699-708, 2005.
22. Liliemark E, Pettersson B, Peterson C and Liliemark J: High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells. J Chromatogr B Biomed Appl 669: 311-317, 1995.
23. Manouilov KK, McGuire TR, Gordon BG and Gwilt PR: Assay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 707: 342-346, 1998.
24. Li XG, Yun JK and Choi JS: Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 28: 151-156, 2007.
25. Carcel-Trullols J, Torres-Molina F, Araico A, Saadeddin A and Peris JE: Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother Pharmacol 54: 153-160,2004.
26. Lo YL and Huang JD: Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats. In Vivo 13: 51-55, 1999.
27. Shin SC, Choi JS and Li X: Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 313: 144-149, 2006.
28. Choi JS, Jo BW and Kim YC: Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 573: 13-18, 2004.